Status:
COMPLETED
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Lead Sponsor:
Julie Krystal
Collaborating Sponsors:
Janssen Pharmaceuticals
Conditions:
Pilomyxoid Astrocytoma
Pilocytic Astrocytoma
Eligibility:
All Genders
1-21 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors. Mebendazole is a d...
Detailed Description
This is a phase I/II study of mebendazole in combination with standard of care agents for pediatric patients with gliomas. Patients with low-grade gliomas will receive a regimen of mebendazole in comb...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age \> 1 year of age and ≤ 21 years of age
- Diagnosis
- 1. Group A - Low-grade Glioma Group:
- Histology: Biopsy-proven:
- Pilocytic Astrocytoma
- Fibrillary Astrocytoma
- Pilomyxoid Astrocytoma
- Pleomorphic Xanthoastrocytoma
- Other low grade astrocytomas
- Children with optic pathway tumors must have evidence of progressive disease on MRI and/or symptoms of deteriorating vision or, progressive hypothalamic/pituitary dysfunction or, diencephalic syndrome or precocious puberty.
- Patients with relapsed low-grade gliomas who have been previously treated with chemotherapy will be eligible for the study provided they have not previously failed therapy with any of the chemotherapeutic agents used in this study.
- 2 Group B - High-grade Glioma/Pontine Glioma Group:
- Histology: Biopsy-proven
- Anaplastic astrocytoma
- Glioblastoma multiforme
- Gliosarcoma.
- Patients with primary spinal cord malignant gliomas are eligible.
- For primary brainstem tumors, histologic verification is not required. Patients are eligible when diagnosed with clinical and radiographic (MRI) evidence of tumors which diffusely involve the brainstem. Patients with tumors which intrinsically (greater than 50% intra-axial) involve the pons or pons and medulla or pons and midbrain or entire brainstem are eligible. Tumors may contiguously involve the thalamus or upper cervical cord.
- Timing of therapy:
- Patients must be enrolled before treatment begins. Treatment must start within 14 days of study enrollment.
- All clinical and laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated in the eligibility section.
- Adequate hematologic, renal, liver function as demonstrated by laboratory values.
- Negative pregnancy test in women of childbearing potential within 7 days of initiating investigational therapy
- Life expectancy ≥ 3 months
- Concurrent medications: It is recommended that patients are weaned off or are on a tapering dose of corticosteroids before starting therapy on study.
- Patient or legal guardian must give written, informed consent or assent (when applicable)
- Recent mothers must agree not to breast feed while receiving medications on study.
- Exclusion criteria:
- Age \< 1 year or \> 21 years
- Patients who have known allergy to mebendazole or benzimidazole class drugs.
- Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection .
- Patients who are taking metronidazole and cannot be safely moved to a different antibiotic greater than 7 days prior to starting mebendazole therapy.
- Pregnant female patients are not eligible for this study. Pregnancy tests with a negative result must be obtained in all post-menarchal females.
- Lactating females must agree they will not breastfeed a child while on this study.
- Males and females of reproductive potential may not participate unless they agree to use an effective contraceptive method and continue to do so for at least 6 months after the completion of therapy.
- Patients who are unable to take oral medications because of significant vomiting will be excluded.
- Group A - Low-grade Glioma Group ONLY:
- Patients who have failed prior chemotherapy with vincristine, carboplatin, or temozolomide for this tumor are excluded.
- Patients with Neurofibromatosis Type 1
- Group B - High-grade Glioma/Pontine Glioma Group ONLY:
- Patients who failed prior chemotherapy with bevacizumab or irinotecan for this tumor are excluded.
- Patients who progressed on or within 12 weeks after completion of radiotherapy are excluded.
- Patients with a history or current condition that would preclude the use of bevacizumab
Exclusion
Key Trial Info
Start Date :
October 22 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01837862
Start Date
October 22 2013
End Date
April 1 2024
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cohen Children's Medical Center of New York
New Hyde Park, New York, United States, 11040